Loading
Alzheimer Dementia (AD) / Fisetin / Alzheimer Dementia · Phase 2 Trial
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed Phase 2 pilot study registration that evaluated fisetin safety and tolerability in 5 older adults with mild cognitive impairment or mild Alzheimer's disease over 30 days. No results or outcome data are posted in this registry record; the study design and population are appropriate for preliminary feasibility work, but efficacy claims cannot be made and safety findings are not yet available.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Alzheimer s Disease, Alzheimer Dementia, Alzheimer Dementia (AD), Alzheimer Disease, Mild Cognitive Disorder, Neurocognitive Disorders, Mild, Neurocognitive Di…; age from 60 Years. Intervention: Fisetin. n = 5. 1 site: Canada.
This is a completed Phase 2 pilot study registration that evaluated fisetin safety and tolerability in 5 older adults with mild cognitive impairment or mild Alzheimer's disease over 30 days. No results or outcome data are posted in this registry record; the study design and population are appropriate for preliminary feasibility work, but efficacy claims cannot be made and safety findings are not yet available.
Primary outcome is safety/tolerability only; no efficacy or cognitive benefit data reported.
No clinical impact can be assessed from this registry record alone, as results are not reported. Clinicians should await publication of safety and tolerability findings before considering fisetin use in this population.
This is a completed Phase 2 pilot study with very small enrollment (n=5) assessing only safety and tolerability of fisetin; no efficacy results are reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be assessed from this registry record alone, as results are not reported. Clinicians should await publication of safety and tolerability findings before considering fisetin use in this population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07279714). This is a study registration, not published results. Lead sponsor: Sunnybrook Health Sciences Centre. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 5 participants (ACTUAL). Conditions: Alzheimer s Disease, Alzheimer Dementia, Alzheimer Dementia (AD), Alzheimer Disease, Mild Cognitive Disorder, Neurocognitive Disorders, Mild, Neurocognitive Disorder. Interventions: OTHER: Fisetin. Primary outcome measures: Incidence of Treatment-Emergent Adverse Events (Safety and tolerability of fisetin) , 30 days. Brief summary: This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.